U.S. markets closed
  • S&P 500

    -55.26 (-1.29%)
  • Dow 30

    -292.30 (-0.86%)
  • Nasdaq

    -260.13 (-2.01%)
  • Russell 2000

    -43.38 (-2.17%)
  • Crude Oil

    -0.59 (-0.65%)
  • Gold

    -10.90 (-0.62%)
  • Silver

    -0.50 (-2.56%)

    -0.0053 (-0.52%)
  • 10-Yr Bond

    +0.1090 (+3.78%)

    -0.0109 (-0.92%)

    +1.0680 (+0.79%)

    -1,618.87 (-7.10%)
  • CMC Crypto 200

    -36.72 (-6.78%)
  • FTSE 100

    +8.52 (+0.11%)
  • Nikkei 225

    -11.81 (-0.04%)

Ocugen (OCGN) to Report Q2 Earnings: What's in the Cards?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Ocugen, Inc. OCGN is likely to provide updates on its pipeline developments when it reports second-quarter 2021 results on Aug 6.

The company has a disappointing earnings surprise history, having missed expectations in three of the trailing four quarters. Its average four-quarter negative earnings surprise was 297.1%. The negative surprise in the last reported quarter was 108%.

Shares of Ocugen have surged 274.3% so far this year against the industry‘s 1.3% decline.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Let’s see how things have shaped up for this announcement.

Factors to Note

With no marketed drugs in its portfolio, Ocugen is unlikely to have recorded any revenues during the second quarter. Furthermore, the company has no clinical-stage candidates in its portfolio.

In February 2021, Ocugen and India-based Bharat Biotech entered into a definitive agreement to co-develop, supply and commercialize Bharat Biotech’s COVAXIN — an advanced-stage whole-virion inactivated COVID-19 vaccine candidate — for the U.S. market. In June 2021, the purview of the agreement was expanded to include the Canadian market.

Ocugen was initially working with both U.S. and Canadian regulatory authorities to develop the regulatory pathway for an emergency use for COVAXIN. However, the company will now pursue submission of a biologics license application (BLA) for its COVID-19 vaccine instead of going for an emergency use in the United States. The change in submission is based on recommendation received from the FDA, and its request for additional data and information. The company is in discussion with the FDA to understand the data requirements and anticipates an additional clinical study to support the BLA submission.

In July 2021, the company announced that Bharat Biotech shared positive results from the phase III study of COVAXIN, which demonstrated an efficacy of 77.8% in mild, moderate and severe COVID-19 disease and an efficacy of 93.4% against severe COVID-19 disease. It also announced that the virus demonstrated efficacy against several SARS-COV-2 variants including efficacy data of 65.2% against the delta variant.

Investor focus will be on COVAXIN-related developments on the company’s earnings call.

Ocugen’s operating expenses are likely to have increased in the quarter under review due to costs related to preparation of IND filing and initiation of the clinical studies.

What Our Model Indicates

Our proven model does not conclusively predict an earnings beat for Ocugen this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.

Earnings ESP: Ocugen has an Earnings ESP of -20.00% as the Most Accurate Estimate of a loss of 4 cents per share is wider than the Zacks Consensus Estimate of a loss of 3 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).

Ocugen, Inc. Price

Ocugen, Inc. Price
Ocugen, Inc. Price

Ocugen, Inc. price | Ocugen, Inc. Quote

Stocks to Consider

Here are some biotech/drug stocks that have the right mix of elements to beat on earnings this time around:

Ironwood IRWD has an Earnings ESP of +11.11% and a Zacks Rank #2.

Moderna MRNA has an Earnings ESP of +24.12% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Prothena Corporation PRTA has an Earnings ESP of +25.66% and a Zacks Rank #3.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report

Moderna, Inc. (MRNA) : Free Stock Analysis Report

Prothena Corporation plc (PRTA) : Free Stock Analysis Report

Ocugen, Inc. (OCGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research